DK1238070T3 - Terapeutisk anvendelige syntetiske oligonucleotider - Google Patents

Terapeutisk anvendelige syntetiske oligonucleotider

Info

Publication number
DK1238070T3
DK1238070T3 DK00981117T DK00981117T DK1238070T3 DK 1238070 T3 DK1238070 T3 DK 1238070T3 DK 00981117 T DK00981117 T DK 00981117T DK 00981117 T DK00981117 T DK 00981117T DK 1238070 T3 DK1238070 T3 DK 1238070T3
Authority
DK
Denmark
Prior art keywords
synthetic oligonucleotides
therapeutically useful
useful synthetic
induction
group
Prior art date
Application number
DK00981117T
Other languages
Danish (da)
English (en)
Inventor
Nigel C Phillips
Mario C Filion
Original Assignee
Bioniche Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioniche Life Sciences Inc filed Critical Bioniche Life Sciences Inc
Application granted granted Critical
Publication of DK1238070T3 publication Critical patent/DK1238070T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK00981117T 1999-12-13 2000-12-12 Terapeutisk anvendelige syntetiske oligonucleotider DK1238070T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17032599P 1999-12-13 1999-12-13
US22892500P 2000-08-29 2000-08-29
PCT/CA2000/001467 WO2001044465A2 (en) 1999-12-13 2000-12-12 Therapeutically useful synthetic oligonucleotides

Publications (1)

Publication Number Publication Date
DK1238070T3 true DK1238070T3 (da) 2007-12-03

Family

ID=26865979

Family Applications (2)

Application Number Title Priority Date Filing Date
DK00981117T DK1238070T3 (da) 1999-12-13 2000-12-12 Terapeutisk anvendelige syntetiske oligonucleotider
DK07015976.9T DK1867718T3 (da) 1999-12-13 2000-12-12 Terapeutisk anvendelige syntetiske oligonucleotider

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK07015976.9T DK1867718T3 (da) 1999-12-13 2000-12-12 Terapeutisk anvendelige syntetiske oligonucleotider

Country Status (18)

Country Link
US (2) US7157436B2 (enExample)
EP (2) EP1867718B1 (enExample)
JP (1) JP4772245B2 (enExample)
KR (1) KR100829646B1 (enExample)
CN (2) CN100445380C (enExample)
AT (2) ATE455851T1 (enExample)
AU (1) AU785212B2 (enExample)
CA (1) CA2393808A1 (enExample)
CZ (1) CZ20022372A3 (enExample)
DE (2) DE60036019T2 (enExample)
DK (2) DK1238070T3 (enExample)
ES (2) ES2288883T3 (enExample)
HU (1) HUP0300627A3 (enExample)
IL (2) IL150196A0 (enExample)
MX (1) MXPA02005842A (enExample)
NO (1) NO330508B1 (enExample)
PT (1) PT1238070E (enExample)
WO (1) WO2001044465A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032610A1 (en) 1996-06-03 2003-02-13 Gilchrest Barbara A. Method to inhibit cell growth using oligonucleotides
US7960540B2 (en) 1999-04-08 2011-06-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US8114850B2 (en) 1999-04-08 2012-02-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
CA2370000A1 (en) 1999-04-08 2000-10-19 Uab Research Foundation Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
DK1238070T3 (da) * 1999-12-13 2007-12-03 Bioniche Life Sciences Inc Terapeutisk anvendelige syntetiske oligonucleotider
AU6886301A (en) 2000-08-29 2002-03-13 Bioniche Life Sciences Inc Modulation of fas and fasl expression
WO2002069369A2 (en) * 2000-12-08 2002-09-06 Coley Pharmaceutical Gmbh Cpg-like nucleic acids and methods of use thereof
US7087586B2 (en) * 2001-04-24 2006-08-08 Bioniche Life Sciences, Inc. Oligonucleotide compositions and their use to induce differentiation of cells
ATE325341T1 (de) * 2001-08-17 2006-06-15 Bioniche Life Sciences Inc Zusammenhang zwischen konformation und biologischer aktivität von apoptose-induzierenden phosphodiesteroligonukleotiden
AU2002341264B2 (en) * 2001-10-03 2007-07-12 Bioniche Life Sciences Inc. Therapeutically useful triethyleneglycol cholesteryl oligonucleotides
MXPA04010415A (es) * 2002-04-22 2005-02-17 Bioniche Life Sciences Inc Composiciones oligonucleotdias y su uso para la modulacion de respuestas inmunes.
US20040235770A1 (en) * 2003-04-02 2004-11-25 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
US7569554B2 (en) * 2003-05-16 2009-08-04 Idera Pharmaceuticals, Inc. Synergistic treatment of cancer using immunomers in conjunction with therapeutic agents
AU2006216493A1 (en) * 2005-02-24 2006-08-31 Coley Pharmaceutical Gmbh Immunostimulatory oligonucleotides
US20090209620A1 (en) * 2005-03-09 2009-08-20 Rong-Fu Wang Direct Reversal Of The Suppressive Function Of CD4+Regulatory T Cells Via Toll-Like Receptor 8 Signaling
GB2443591B (en) * 2005-09-07 2010-04-28 Secr Defence Adjuvanted vaccine
CA2752239C (en) * 2009-02-12 2021-03-30 Opko Curna, Llc Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
KR100998365B1 (ko) 2009-06-29 2010-12-06 압타바이오 주식회사 치료 효능이 있는 변형핵산 및 구아노신을 함유하는 올리고뉴클레오티드 변형체
EP2490767A4 (en) * 2009-07-15 2013-02-13 Santaris Pharma As GLI2 TARGETING TARGET ANTAGONIST FOR THE TREATMENT OF LEUKEMIA
WO2013129603A1 (ja) * 2012-02-28 2013-09-06 国立大学法人東京農工大学 Tdp-43細胞内存在量関連疾患の認定方法
EP4000597A1 (en) * 2020-11-17 2022-05-25 The Boots Company plc Tetrapeptide and compositions comprising tetrapeptides
WO2023122762A1 (en) 2021-12-22 2023-06-29 Camp4 Therapeutics Corporation Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172815A (en) * 1962-04-24 1965-03-09 Warner Lambert Pharmaceutical Method for preparing reticulo-endo-thelial system stimulant and stimulant thereof
FR2160326B1 (enExample) * 1971-11-19 1975-02-07 Anvar
US4152423A (en) * 1971-11-19 1979-05-01 Agence Nationale De Valorisation De La Recherche (Anvar) Immunological agents
CA1020460A (en) * 1973-02-23 1977-11-08 Wellcome Foundation Limited (The) Isolation of immunostimulating glycopeptide from bacteria
US3976544A (en) * 1973-06-19 1976-08-24 The Agence Nationale De Valorisation De Le Recherche Water-soluble immunological adjuvants, in particular for vaccines, obtained from mycobacteria and related microorganisms and process for their extraction
FR2374042A1 (fr) * 1976-06-04 1978-07-13 Merieux Inst Nouveau medicament immunostimulant et son procede de preparation
JPS54140710A (en) * 1978-03-10 1979-11-01 Mitsui Toatsu Chem Inc Anti-tumor substance and its preparation
DE3011461C2 (de) * 1980-03-25 1986-10-30 Dr. Madaus & Co, 5000 Köln Verwendung von Propionibakterien
US4520019A (en) * 1982-04-29 1985-05-28 Ribi Immunochem Research, Inc. Stable composition and preparation thereof
US4579941A (en) * 1982-08-13 1986-04-01 Mitsuitoatsu Chemicals, Inc. Thermally-denatured deoxyribonucleic acid MD-011 and antitumor agent
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
US4744984A (en) * 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
DE3723075A1 (de) * 1987-07-11 1989-01-19 Boehringer Mannheim Gmbh Eukaryotische expressionsvektoren mit multimeren enhancer-subelementen, verfahren zu ihrer herstellung und verwendung
US4958013A (en) * 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
WO1992007095A1 (en) * 1990-10-15 1992-04-30 Stratagene Arbitrarily primed polymerase chain reaction method for fingerprinting genomes
AU1456092A (en) * 1991-02-21 1992-09-15 Gilead Sciences, Inc. Aptamers specific for thrombin and methods of use
AU739601B2 (en) * 1991-07-03 2001-10-18 Meditech Research Limited Use of hyaluronan in gene therapy
US5582981A (en) * 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
IL107150A0 (en) * 1992-09-29 1993-12-28 Isis Pharmaceuticals Inc Oligonucleotides having a conserved g4 core sequence
ATE179333T1 (de) * 1993-01-29 1999-05-15 Vetrepharm Inc Immunotherapeutische zubereitung
US5567604A (en) * 1993-04-23 1996-10-22 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich oligonucleotides
CN1154702A (zh) * 1994-05-25 1997-07-16 海布里登公司 具有抗巨细胞病毒活性的寡核苷酸
DE69533037T2 (de) * 1994-08-30 2005-05-04 Commonwealth Scientific And Industrial Research Organisation Pflanzentraskriptionsregulator von circovirus
US5643890A (en) * 1995-01-31 1997-07-01 The Board Of Regents Of The University Of Nebraska Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases
IN181358B (enExample) * 1995-02-14 1998-05-30 Bioniche Inc
ZA964446B (en) * 1995-06-06 1996-12-06 Hoffmann La Roche Oligonucleotides specific for hepatitis c virus
US5990299A (en) * 1995-08-14 1999-11-23 Icn Pharmaceuticals, Inc. Control of CD44 gene expression for therapeutic use
JPH11507245A (ja) * 1995-11-21 1999-06-29 アイシーエヌ・ファーマシューティカルズ・インコーポレイテッド Ｉｌ―８およびｉｌ―８受容体に対するアンチセンスオリゴヌクレオチドによる睡瘍増殖の阻害
IT1277025B1 (it) 1995-12-04 1997-11-04 Cooperativa Centro Ricerche Po Classe di oligonucleotidi fosfodiesterici ad attivita' citotossica composizioni farmaceutiche che li contengono e loro uso
US6015710A (en) * 1996-04-09 2000-01-18 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
AU737926B2 (en) * 1996-05-20 2001-09-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Oligonucleotides which specifically bind retroviral nucleocapsid proteins
AU736450B2 (en) * 1997-08-05 2001-07-26 Bioniche Urology Ip Inc. Composition and method for regulating cell proliferation and cell death
US6255473B1 (en) * 1997-08-29 2001-07-03 Duke University Presenilin-1 gene promoter
WO2001022972A2 (en) * 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids
DK1238070T3 (da) * 1999-12-13 2007-12-03 Bioniche Life Sciences Inc Terapeutisk anvendelige syntetiske oligonucleotider
US20020091095A1 (en) * 1999-12-13 2002-07-11 Phillips Nigel C. Modulation of Fas and FasL expression
JP4215429B2 (ja) * 1999-12-28 2009-01-28 バイオニケ ライフ サイエンシーズ インコーポレイテッド 癌治療におけるヒアルロン酸
AU2002341264B2 (en) * 2001-10-03 2007-07-12 Bioniche Life Sciences Inc. Therapeutically useful triethyleneglycol cholesteryl oligonucleotides
MXPA04010415A (es) * 2002-04-22 2005-02-17 Bioniche Life Sciences Inc Composiciones oligonucleotdias y su uso para la modulacion de respuestas inmunes.

Also Published As

Publication number Publication date
US20070213291A1 (en) 2007-09-13
AU1847901A (en) 2001-06-25
NO20022820D0 (no) 2002-06-13
IL150196A0 (en) 2002-12-01
EP1867718A2 (en) 2007-12-19
CZ20022372A3 (cs) 2002-11-13
NO330508B1 (no) 2011-05-09
ES2340807T3 (es) 2010-06-09
AU785212B2 (en) 2006-11-09
NO20022820L (no) 2002-08-08
EP1238070A2 (en) 2002-09-11
HUP0300627A2 (hu) 2004-06-28
DE60043759D1 (de) 2010-03-11
EP1238070B1 (en) 2007-08-15
US20010041681A1 (en) 2001-11-15
CN101491536A (zh) 2009-07-29
CN101491536B (zh) 2012-07-04
CN1433469A (zh) 2003-07-30
WO2001044465A2 (en) 2001-06-21
IL150196A (en) 2009-06-15
CN100445380C (zh) 2008-12-24
KR100829646B1 (ko) 2008-05-16
DE60036019D1 (de) 2007-09-27
EP1867718B1 (en) 2010-01-20
ATE455851T1 (de) 2010-02-15
KR20020079752A (ko) 2002-10-19
DK1867718T3 (da) 2010-04-12
JP4772245B2 (ja) 2011-09-14
CA2393808A1 (en) 2001-06-21
DE60036019T2 (de) 2008-05-29
MXPA02005842A (es) 2003-10-14
PT1238070E (pt) 2007-11-06
EP1867718A3 (en) 2008-04-02
ATE370231T1 (de) 2007-09-15
JP2003517041A (ja) 2003-05-20
ES2288883T3 (es) 2008-02-01
HUP0300627A3 (en) 2005-11-28
US7157436B2 (en) 2007-01-02
WO2001044465A3 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
DK1238070T3 (da) Terapeutisk anvendelige syntetiske oligonucleotider
GB2340121B (en) Delivery system
FI924574A7 (fi) Geeniterapia sairauksiin, jotka liittyvät solujen nopeaan lisääntymise en
GB0026498D0 (en) Bioinformatic transaction scheme
TW453437U (en) Bulletproof vest
MXPA03009132A (es) Alquilhidroxamatos triciclicos, su preparacion y su uso como inhibidores de la proliferacion de celulas.
ZA200003404B (en) Bunching resistant absorbent article.
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
ZA200005186B (en) Thermal Shock-resistant ceramic article.
AU7720800A (en) Engineered radiation resistant bioremediating bacteria
IL142895A0 (en) Adenine nucleotide translocator polyptides
ZA9811378B (en) Graft copolymers as gene carriers.
IL163672A0 (en) Microorganisms as carriers of nucleotide sequencescoding for cell antigens used for the treatment o f tumors
GB9807114D0 (en) Novel process
PH31659A (en) Therapeutic nucleotides.
MXPA04002530A (es) Oligonucleotidos de treitilenglicol colesteril terapeuticamente utiles.
AU1351501A (en) Gene sequences identified by protein motif database searching
WO1998000544A3 (en) Growth arrest gene compositions and methods
GB9921938D0 (en) Target for antiviral therapy
GB2367097A9 (en) Deriving energy from atmospheric temperature
CA2103062A1 (en) Oligo-2'-deoxynucleotides and their use as pharmaceutical agents with antiviral activity
CA95581S (en) Hat
ITMI920892A1 (it) Selezione genica in vitro mediante vettori ad rna
EP0533926A4 (en) NUCLEOTIDE DERIVATIVE.
ZA200003586B (en) Therapeutic article.